Cargando…

Autonomic nervous system dysfunction in schizophrenia: impact on cognitive and metabolic health

Schizophrenia (SCZ) is a psychiatric disorder characterized by a wide range of positive, negative and cognitive symptoms, along with an increased risk of metabolic syndrome and cardiovascular disease that contribute to a 15–20-year reduced life expectancy. Autonomic dysfunction, in the form of incre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stogios, Nicolette, Gdanski, Alexander, Gerretsen, Philip, Chintoh, Araba F., Graff-Guerrero, Ariel, Rajji, Tarek K., Remington, Gary, Hahn, Margaret K., Agarwal, Sri Mahavir
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8076312/ https://www.ncbi.nlm.nih.gov/pubmed/33903594 http://dx.doi.org/10.1038/s41537-021-00151-6

Ejemplares similares

Outcomes and clinical implications of intranasal insulin on cognition in humans: A systematic review and meta-analysis
por: Wu, Sally, et al.
Publicado: (2023)

Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia
por: MacKenzie, Nicole E., et al.
Publicado: (2018)

T231. QUALITY OF LIFE IN ANTIPSYCHOTIC-NAïVE YOUTH: EXPLORING THE INTERPLAY WITH METABOLIC SIDE-EFFECTS
por: Chintoh, Araba, et al.
Publicado: (2020)

Gut microbiome in schizophrenia and antipsychotic-induced metabolic alterations: a scoping review
por: Singh, Raghunath, et al.
Publicado: (2022)

Exploring Patterns of Disturbed Eating in Psychosis: A Scoping Review
por: Stogios, Nicolette, et al.
Publicado: (2020)

M84. METFORMIN FOR EARLY CO-MORBID PREDIABETES OR DIABETES IN SCHIZOPHRENIA SPECTRUM DISORDERS: A DOUBLE BLIND RANDOMIZED PILOT STUDY
por: Mahavir Agarwal, Sri, et al.
Publicado: (2020)

Investigating the effects of antipsychotics on brain insulin action: Study protocol for a multi-modality magnetic resonance imaging (MRI) study in healthy controls
por: Stogios, Nicolette, et al.
Publicado: (2022)

S89. INVESTIGATING METABOLIC DYSFUNCTION AND METABOLOMIC PROFILE CHANGES IN ANTIPSYCHOTIC NAIVE PATIENTS
por: Costa-Dookhan, Kenya, et al.
Publicado: (2020)

Metformin for early comorbid glucose dysregulation and schizophrenia spectrum disorders: a pilot double-blind randomized clinical trial
por: Agarwal, Sri Mahavir, et al.
Publicado: (2021)

S90. A SYSTEMATIC REVIEW AND META-ANALYSIS OF PHARMACOLOGICAL INTERVENTIONS FOR REDUCTION OF WEIGHT GAIN IN PEOPLE WITH SCHIZOPHRENIA: 2019 UPDATE
por: Agarwal, Sri Mahavir, et al.
Publicado: (2020)

Associations between plasma clozapine/N-desmethylclozapine ratio, insulin resistance and cognitive performance in patients with co-morbid obesity and ultra-treatment resistant schizophrenia
por: Costa-Dookhan, Kenya A., et al.
Publicado: (2021)

Metformin for the treatment of antipsychotic-induced metabolic disturbances in people with intellectual and developmental disabilities
por: Stogios, Nicolette, et al.
Publicado: (2023)

Non-invasive neuromodulation of dorsolateral prefrontal cortex to reduce craving in alcohol use disorder: A meta-analysis
por: Sorkhou, Maryam, et al.
Publicado: (2022)

Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin – a case series
por: Prasad, Femin, et al.
Publicado: (2023)

Favourable cognitive changes observed with metabolic improvements in a patient with severe mental illness
por: van Reekum, Emma A, et al.
Publicado: (2023)

Characterization and prediction of individual functional outcome trajectories in schizophrenia spectrum disorders (PREDICTS study): Study protocol
por: Agarwal, Sri Mahavir, et al.
Publicado: (2023)

Metabolomic signatures associated with weight gain and psychosis spectrum diagnoses: A pilot study
por: Lee, Jiwon, et al.
Publicado: (2023)

Impaired illness awareness in schizophrenia and posterior corpus callosal white matter tract integrity
por: Gerretsen, Philip, et al.
Publicado: (2019)

Pharmacological Interventions to Treat Antipsychotic-Induced Dyslipidemia in Schizophrenia Patients: A Systematic Review and Meta Analysis
por: Kanagasundaram, Pruntha, et al.
Publicado: (2021)

S225. A SYSTEMATIC REVIEW AND META-ANALYSIS OF PHARMACOLOGICAL INTERVENTIONS FOR REDUCTION OR PREVENTION OF WEIGHT GAIN IN SCHIZOPHRENIA
por: Agarwal, Sri Mahavir, et al.
Publicado: (2018)

The Complex Relationship between Antipsychotic-Induced Weight Gain and Therapeutic Benefits: A Systematic Review and Implications for Treatment
por: Raben, Alex T., et al.
Publicado: (2018)

F178. NEUROANATOMICAL PROFILES OF TREATMENT-RESISTANCE IN PATIENTS WITH SCHIZOPHRENIA
por: Plitman, Eric, et al.
Publicado: (2018)

Metabolic Syndrome in Schizophrenia: Theoretical, Clinical and Translational Perspectives
por: Agarwal, Sri Mahavir, et al.
Publicado: (2013)

S76. A BEHAVIOURAL ECONOMIC ANALYSIS OF EFFORT-RELATED CHOICE IN SCHIZOPHRENIA
por: Fervaha, Gagan, et al.
Publicado: (2018)

S175. AMOTIVATION IS ASSOCIATED WITH SMALLER VENTRAL STRIATUM VOLUMES IN OLDER PATIENTS WITH SCHIZOPHRENIA
por: Caravaggio, Fernando, et al.
Publicado: (2018)

Cortical thinning in relation to impaired insight into illness in patients with treatment resistant schizophrenia
por: Kim, Julia, et al.
Publicado: (2023)

Glutathione Levels and Glutathione-Glutamate Correlation in Patients With Treatment-Resistant Schizophrenia
por: Iwata, Yusuke, et al.
Publicado: (2021)

S16. GLUTAMATERGIC NEUROMETABOLITE LEVELS IN PATIENTS WITH TREATMENT-RESISTANT SCHIZOPHRENIA: A CROSS-SECTIONAL 3T PROTON MRS STUDY
por: Iwata, Yusuke, et al.
Publicado: (2018)

Reduced Insulin Sensitivity Is Related to Less Endogenous Dopamine at D(2/3) Receptors in the Ventral Striatum of Healthy Nonobese Humans
por: Caravaggio, Fernando, et al.
Publicado: (2015)

Sequential drug treatment algorithm for agitation and aggression in Alzheimer’s and mixed dementia
por: Davies, Simon JC, et al.
Publicado: (2018)

Dimensional distribution of cortical abnormality across antipsychotics treatment-resistant and responsive schizophrenia
por: Itahashi, Takashi, et al.
Publicado: (2021)

Editorial: Cardiovascular and Physical Health in Severe Mental Illness
por: Agarwal, Sri Mahavir, et al.
Publicado: (2021)

Differential Methylation Analysis of Suicidal Ideation Severity in Schizophrenia with the Illumina MethylationEPIC Array
por: Wang, Kevin Z., et al.
Publicado: (2022)

Cognitive Mapping Deficits in Schizophrenia: A Critical Overview
por: Bose, Anushree, et al.
Publicado: (2014)

Getting Into the Zone: A Pilot Study of Autonomic-Cardiac Modulation and Flow State During Piano Performance
por: Jha, Shreya, et al.
Publicado: (2022)

Treating Negative Symptoms in Schizophrenia: an Update
por: Remington, Gary, et al.
Publicado: (2016)

Decreased cortical gyrification and surface area in the left medial parietal cortex in patients with treatment‐resistant and ultratreatment‐resistant schizophrenia
por: Kitajima, Kazutoshi, et al.
Publicado: (2022)

Dose-dependent effect of antipsychotic drugs on autonomic nervous system activity in schizophrenia
por: Iwamoto, Yohko, et al.
Publicado: (2012)

Altered Heart Rate Variability in Patients With Schizophrenia During an Autonomic Nervous Test
por: Liu, Ya, et al.
Publicado: (2021)

Schizophrenia Hypothesis: Autonomic Nervous System Dysregulation of Fetal and Adult Immune Tolerance
por: Carnac, Tamara
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i75mqtmp34hsk4p4rr67bruajs